Clint is part of the class of 1991. In 1995, Mr. Schmidt earned a Bachelor of Science degree in Microbiology from the University of Minnesota. In 2000, he earned a Doctor of Philosophy degree in Immunology from the U of M. From 2003-2008, he was a scientific team member at Dendreon (Seattle, WA) that developed the first FDA-approved Autologous Cellular Immunotherapy (PROVENGEⓇ, sipuleucel-T) for prostate cancer. Since 2009, Mr. Schmidt has been the Director of Operations for NovaDigm Therapeutics, Inc.  (Grand Forks) which develops vaccines to prevent bacterial and fungal infections. He is also an Adjunct Assistant Professor at the University of North Dakota School of Medicine and Health Sciences.